Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
6.55    0.00 (0.00%)
Bid:
6.20
Ask:
6.90
Spread: 0.70 (11.29%)
Market Cap: £70.42m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Net Asset Value(s)

8 Oct 2019 07:00

RNS Number : 0508P
Agronomics Limited
08 October 2019
 

8 October 2019

Agronomics Limited

(the "Company")

Net Asset Value calculation to 30 September 2019

Richard Reed, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2019 was 5.50 pence per share, including un-invested cash of £3,463,359. The portfolio is valued under IFRS at bid price. I am pleased to note that the share price of 6.75 pence at 30 September 2019 close represents a premium of 22% to the NAV. Net Assets stand at £6.3 million, including investments of £2.8 million. This quarter's NAV per share represents a decrease of 23% from the previous valuation of 7.17 pence per share, which included un-invested cash of £417,952. The reduction is largely as a result of the increase in issued shares following the fundraise. No management fee is due to Shellbay Investments Limited.

Following completion of a successful fundraise during July 2019, the proceeds are now available for deployment in line with the new investment policy.

On 29 July 2019, the Company completed a subscription of US$ 699,999.54 for 885,739 Series Seed Preferred Shares in Simply Foods, Inc. ("Simply Foods") trading as New Age Meats, a company based in San Francisco, California, USA, that is developing pork-based cultured meat products. The Subscription was part of the first close of the Series Seed funding round to raise a minimum of US$ 2.0 million undertaken by Simply Foods, led by New York-based ff Graphite (V) Venture Capital Fund, LP. The Company was the only European based investor participating in this round, and remains the only UK quoted vehicle offering investors exposure to this rapidly growing sector.

On 29 August 2019, the Company completed a subscription of US$ 749,990 for 40,540 Series A Preferred Shares in BlueNalu, Inc. ("BlueNalu"), a global leader in cellular aquaculture. The subscription increased the Company's existing interest in BlueNalu to approximately 2.59%. The subscription was part of the Series A funding round undertaken by BlueNalu, and co-led by Stray Dog Ventures LLC, Clear Current Capital Fund, LLC, CPT Capital Fund, LLP and New Crop Capital Trust - four prominent investors in the alternative protein sector. The price per share of the subscription represented a multiple uplift of approximately 3.2x since the Company's original investment in BlueNalu of US$250,000 in August 2018.

On 5 September 2019, the Company subscribed for US $150,000 of convertible promissory notes in Bond Pets LLC ("Bond"). Bond makes laboratory-grown meat using fermentation for the pet food market. The subscription would translate to an approximate 3% to 4% equity interest in Bond, dependent on the valuation of Bond upon conversion.

 

Your board continues to evaluate a number of opportunities which show significant growth prospects".

Unaudited to

30 September 2019 £

Fixed Assets

Investments

2,827,203

Current Assets

Uninvested cash

3,463,359

Sundry Debtors

34,355

Current Liabilities

Trade and other creditors

(61,841)

6,263,076

Capital and Reserves

Share Capital

23

Share Premium

6,420,142

Reserves

(157,089)

6,263,076

Shares in Issue

113,795,558

Net Asset Value per share

5.50 pence

 

 

Portfolio Details

Investments as at 30 September 2019

Value

% of Total Portfolio

AgeX Therapeutics Inc

197,193

6.97%

Regent Pacific Group Limited

210,871

7.46%

Portage Biotech Inc

216,845

7.67%

Other quoted holdings

7,627

0.27%

Other unquoted holdings

2,194,667

77.63%

Total

2,827,203

100.00%

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain. 

 

For further information, please contact:

Agronomics Limited

Beaumont Cornish Limited

Optiva Securities Limited

Peterhouse Capital Limited

Britton Financial PR

The Company

Nomad

Joint Broker

Joint Broker

Investor Relations

Denham Eke

+44 (0) 1624 639396

Roland Cornish/James Biddle

+44 (0) 207 628 3396

Jeremy King

+44 (0) 203 137 1904

Lucy Williams

+44 (0) 207 469 0936

 

Tim Blackstone

+44 (0)7957 140416

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVBLBDGUBGBGCR
Date   Source Headline
4th Feb 20257:00 amRNSNet Asset Value calculation as at 31 December 2024
30th Jan 20257:00 amRNSLiberation Labs Closes US$ 50.5 million Fundraise
21st Jan 20254:33 pmRNSFormo Secures a €35 million loan
24th Dec 202412:37 pmRNSFinal Results and Notice of AGM
13th Dec 20243:55 pmRNSExercise of Warrants, Total Voting Rights
28th Nov 20247:00 amRNSNet Asset Value calculation at 30 September 2024
27th Nov 20247:00 amRNS-RAll G Co Update
15th Oct 20244:36 pmRNSAgronomics invests US$ 2m in Liberation Labs
15th Oct 20247:00 amRNSAgronomics invests US$2m in Liberation Labs
10th Oct 20244:20 pmRNSJim Mellon – Director’s Dealing and PDMR
8th Oct 202411:30 amRNSJim Mellon – Director’s Dealing and PDMR
7th Oct 202411:52 amRNSExercise of Warrants & TVR
4th Oct 20241:57 pmRNSHolding(s) in Company
27th Sep 20247:00 amRNSShellbay Appoints New Chief Executive Officer
24th Sep 20249:00 amRNSMeatable awarded €7.6 million Innovation Credit
10th Sep 20247:00 amRNSFormo Closes a US$ 61 Million Series B Round
4th Sep 20247:00 amRNSGALY Raises US$ 33 Million in Series B Financing
8th Aug 20245:13 pmRNSHolding(s) in Company
8th Aug 20247:00 amRNSNAV Statement, Warrant Exercise, TVR
18th Jul 20247:00 amRNSOnego Bio Secures EUR 14 million in New Funding
17th Jul 20248:00 amRNSMeatly Receives Clearance for Cultivated Pet Food
6th Jun 20247:00 amRNSExercise of Warrants & TVR
29th May 20247:00 amRNSPortfolio Company Presentation – Clean Food Group
23rd May 20241:01 pmRNSMeatable Appoints Jeff Tripician as New CEO
7th May 20247:00 amRNSNet Asset Value calculation as at 31 March 2024
7th May 20247:00 amRNSMeatly Unveils Protein-Free Medium
26th Apr 20247:00 amRNSSolar Foods Raises an Additional EUR8 Million
22nd Apr 20247:00 amRNSAgronomics Newsletter
17th Apr 20247:00 amRNSMosa Meat Raises EUR 40 Million in New Financing
12th Apr 20247:00 amRNSExercise of Warrants
10th Apr 20249:30 amRNSPortfolio Company Presentation Series – Onego Bio
5th Apr 20247:00 amRNSAgronomics Invests US$10m in Liberation Labs
2nd Apr 20247:00 amRNSOnego Bio Raises EUR37 Million
26th Mar 20247:09 amRNSClean Food secures £2.5m additional funding
21st Mar 20245:40 pmRNSSuperMeat Update
20th Mar 202410:37 amRNSFormo Update
18th Mar 20247:00 amRNSMeatly Creates Cans of Cultivated Pet Food
13th Mar 20247:00 amRNSShiok Meats Merges with Umami Bioworks
21st Feb 20247:00 amRNSAgronomics Newsletter
14th Feb 20247:00 amRNSCalifornia Cultured Update
14th Feb 20247:00 amRNSUnaudited Interim Results
9th Feb 20247:00 amRNSNet Asset Value calculation as at 31 December 2023
8th Feb 202412:15 pmRNSResult of AGM
8th Feb 20247:00 amRNSPerformance Shares issued to Shellbay Investments
6th Feb 20247:00 amRNSBond Pet Foods Achieves Key Milestone
18th Jan 20247:00 amRNSIsraFirst Regulatory Approval for Cultivated Beef
10th Jan 202412:32 pmRNSAgronomics Newsletter
10th Jan 20247:00 amRNSExercise of Warrants and TVR
28th Dec 202312:36 pmRNSNew Website and Corporate Presentation
27th Dec 20231:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.